Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Flortaucipir F-18

FDA-approved product (solution, intravenous), marketed as Tauvid.

Registered studies
30
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Flortaucipir F-18
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Alzheimer disease
  • Cognitive impairment
  • Neurodegenerative disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other central nervous system diagnostic radiopharmaceuticals
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli24.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis42.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

30registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Flortaucipir F-18 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Flortaucipir F-18 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

    NCT06297590 · start 2024-08-15

    Registered record
    Registry ID
    NCT06297590
    Conditions
    Alzheimer Disease
    Interventions
    LY3954068; Placebo; Flortaucipir F18
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2024-08-15
    Completion
    2027-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionLY3954068; Placebo; Flortaucipir F18
    PhasePhase 1
    Registry statusRecruiting

  • Alzheimer's Disease Neuroimaging Initiative 4

    NCT05617014 · start 2023-06-09

    Registered record
    Registry ID
    NCT05617014
    Conditions
    Mild Cognitive Impairment; Alzheimer Disease; Dementia
    Interventions
    Neuraceq; Amyvid; Tauvid; MK-6240; NAV4694; PI-2620
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2023-06-09
    Completion
    2027-07-31
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment; Alzheimer Disease; Dementia
    InterventionNeuraceq; Amyvid; Tauvid; MK-6240 +2 more
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • Imaging of Brain Structural/Functional Connectivity and Amyloid and Tau Lesions in APOE4 Carriers.

    NCT03816228 · start 2022-01

    Registered record
    Registry ID
    NCT03816228
    Conditions
    Alzheimer Disease
    Interventions
    F 18 T807 Flortaucipir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2022-01
    Completion
    2022-10-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionF 18 T807 Flortaucipir
    PhaseNot recorded
    Registry statusWithdrawn

  • Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)

    NCT04579120 · start 2021-09-01

    Registered record
    Registry ID
    NCT04579120
    Conditions
    Alzheimer Disease
    Interventions
    [11C]-Pittsburgh Compound B ([11C]PiB); F 18 AV-1451 (Flortaucipir)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-09-01
    Completion
    2027-12
    Enrolment
    650

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    Intervention[11C]-Pittsburgh Compound B ([11C]PiB); F 18 AV-1451 (Flortaucipir)
    PhaseNot recorded
    Registry statusRecruiting

  • Depression and Driving

    NCT05446805 · start 2021-06-17

    Registered record
    Registry ID
    NCT05446805
    Conditions
    Depression; Drive
    Interventions
    F 18 AV-1451 (Flortaucipir); [11C]-Pittsburgh Compound B ([11C]PiB)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2021-06-17
    Completion
    2027-12-17
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Drive
    InterventionF 18 AV-1451 (Flortaucipir); [11C]-Pittsburgh Compound B ([11C]PiB)
    PhaseNot recorded
    Registry statusRecruiting

  • NFL LONG Prospective Study

    NCT04263337 · start 2020-03-12

    Registered record
    Registry ID
    NCT04263337
    Conditions
    Concussion, Brain
    Interventions
    [11C] PiB; [18F] PBR111; [18F] Flortaucipir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2020-03-12
    Completion
    2028-08
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConcussion, Brain
    Intervention[11C] PiB; [18F] PBR111; [18F] Flortaucipir
    PhasePhase 1
    Registry statusActive not recruiting

  • Evaluation of Flortaucipir PET Signal and Cognitive Change in Early Alzheimer's Disease

    NCT03901105 · start 2019-03-28

    Registered record
    Registry ID
    NCT03901105
    Conditions
    Alzheimer Disease
    Interventions
    flortaucipir F18; Brain PET Scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-28
    Completion
    2019-04-28
    Enrolment
    205

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    Interventionflortaucipir F18; Brain PET Scan
    PhasePhase 3
    Registry statusCompleted

  • A Reader Study to Assess Accuracy and Reliability of Flortaucipir F 18 Positron Emission Tomography (PET) Scan Interpretation

    NCT03901092 · start 2019-03-26

    Registered record
    Registry ID
    NCT03901092
    Conditions
    Alzheimer Disease
    Interventions
    flortaucipir F 18
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-03-26
    Completion
    2019-04-26
    Enrolment
    242

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    Interventionflortaucipir F 18
    PhasePhase 3
    Registry statusCompleted

  • Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study

    NCT04080544 · start 2019-01-15

    Registered record
    Registry ID
    NCT04080544
    Conditions
    Alzheimer Disease; Cognitive Decline
    Interventions
    [18F]AV-1451; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-01-15
    Completion
    2022-06-30
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease; Cognitive Decline
    Intervention[18F]AV-1451; Positron Emission Tomography
    PhasePhase 2
    Registry statusCompleted

  • Longitudinal Early-onset Alzheimer's Disease Study Protocol

    NCT03507257 · start 2018-04-30

    Registered record
    Registry ID
    NCT03507257
    Conditions
    Early Onset Alzheimer Disease; Alzheimer Disease; Mild Cognitive Impairment
    Interventions
    Flortaucipir; Florbetaben; Fluorodeoxyglucose
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2018-04-30
    Completion
    2027-01-01
    Enrolment
    850

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEarly Onset Alzheimer Disease; Alzheimer Disease; Mild Cognitive Impairment
    InterventionFlortaucipir; Florbetaben; Fluorodeoxyglucose
    PhaseNot recorded
    Registry statusActive not recruiting

  • Tau Screening Study in Subjects With Early Symptomatic AD

    NCT03467477 · start 2018-03-08

    Registered record
    Registry ID
    NCT03467477
    Conditions
    Alzheimer Disease
    Interventions
    Flortaucipir F18; Brain PET Scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-03-08
    Completion
    2018-11-15
    Enrolment
    161

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionFlortaucipir F18; Brain PET Scan
    PhasePhase 2
    Registry statusCompleted

  • Tau Screening Study in Patients With Early Symptomatic AD

    NCT03322462 · start 2017-11-21

    Registered record
    Registry ID
    NCT03322462
    Conditions
    Alzheimer Disease
    Interventions
    Flortaucipir F18; Brain PET Scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-11-21
    Completion
    2018-08-31
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionFlortaucipir F18; Brain PET Scan
    PhasePhase 2
    Registry statusCompleted

  • Flortaucipir PET Imaging in Subjects With FTD

    NCT03040713 · start 2017-04-11

    Registered record
    Registry ID
    NCT03040713
    Conditions
    Frontotemporal Dementia
    Interventions
    Flortaucipir F18; Brain PET scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-04-11
    Completion
    2018-10-24
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFrontotemporal Dementia
    InterventionFlortaucipir F18; Brain PET scan
    PhasePhase 1
    Registry statusCompleted

  • Flortaucipir 18F PET Imaging in BIOCARD Study

    NCT03052972 · start 2017-03-23

    Registered record
    Registry ID
    NCT03052972
    Conditions
    Cognitive Decline
    Interventions
    Flortaucipir F18; Brain PET scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2017-03-23
    Completion
    2018-08-17
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCognitive Decline
    InterventionFlortaucipir F18; Brain PET scan
    PhasePhase 1
    Registry statusTerminated

  • A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease

    NCT03019536 · start 2017-01-31

    Registered record
    Registry ID
    NCT03019536
    Conditions
    Alzheimer Disease
    Interventions
    LY3303560 - IV; Placebo - IV; Florbetapir F 18; Flortaucipir F18
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-01-31
    Completion
    2019-06-05
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlzheimer Disease
    InterventionLY3303560 - IV; Placebo - IV; Florbetapir F 18; Flortaucipir F18
    PhasePhase 1
    Registry statusCompleted